Research Papers:
Prognostic value of increased KPNA2 expression in some solid tumors: A systematic review and metaanalysis
PDF | Full Text | Supplementary Files | How to cite
Metrics: PDF 3208 views | Full Text 3652 views
Li-Na Zhou1,2,*, Yue Tan1,2,*, Ping Li1,2,*, Ping Zeng2, Min-Bin Chen2, Ye Tian1, Ya-Qun Zhu1
1Department of Radiotherapy and Oncology, the Second Affiliated Hospital of Soochow University, Institute of Radiotherapy & Oncology, Soochow University, Suzhou, Jiangsu 215004, China
2Department of Radiotherapy and Oncology, Kunshan First People’s Hospital Affiliated to Jiangsu University, Kunshan 215300, Jiangsu Province, China
*These authors have contributed equally to this work and should be considered co-first authors
Correspondence to:
Ya-Qun Zhu, email: [email protected]
Keywords: KPNA2, tumor, prognosis, overall survival
Received: July 04, 2016 Accepted: November 14, 2016 Published: December 10, 2016
ABSTRACT
Background: Karyopherin α2 (KPNA2), a member of the Karyopherin α family, has recently been reported to play an important role in tumor progression. However, the association between KPNA2 expression and prognosis in cancer remains controversial. So we performed this meta-analysis to evaluate whether expression of KPNA2 was associated with prognosis in patients with solid tumor.
Methods/Findings: 24 published eligible studies, including 6164 cases, were identified and included in this meta-analysis through searching of PubMed, EMBASE and Web of Science. We found that KPNA2 expression was an independent predictor for the prognosis of solid tumor with primary outcome (overall survival [OS]: pooled HR=1.767, 95% CI=1.503-2.077, P<0.001) and secondary outcomes (time to recurrence [TTR], recurrence free survival [RFS] and progression free survival [PFS]). However, the association between KPNA2 overexpression and disease free survival [DFS] in solid tumors was not significant (pooled HR=1.653, 95% CI=0.903-3.029, P=0.104). Furthermore, the subgroup analysis revealed that KPNA2 overexpression was associated with poor OS in East-Asian patients and European patients, as well as patients with gastric and colorectal cancer.
Conclusion: KPNA2 expression may be a useful prognostic biomarker to monitor cancer prognosis. Further prospective studies with larger sample sizes are required to confirm our findings.